Literature DB >> 11063872

An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation.

K U Birkenkamp1, M T Esselink, W Kruijer, E Vellenga.   

Abstract

In this study, we examined the involvement of the phosphatidylinositol 3-kinase (PI3-K) and p70S6 kinase signal transduction pathway in the interleukin-1(IL-1)-mediated proliferation and cytokine production by normal and leukemic myeloid cells. Total AML blast populations, early progenitor (CD34(+)/CD36(-)) cells, and more differentiated (CD34(-)/CD36(+)) cells were treated with the PI3-K inhibitor Ly294002 and p70S6K inhibitor rapamycin. The effects on proliferation, IL-6 protein secretion, and intracellular signaling cascades were determined and compared with normal CD34(+) cells and monocytes. The function of the PI3-K pathway was dependent on the differentiation state of the AML cell population. In immature blasts, the IL-1-induced proliferation was strongly inhibited by Ly294002 and rapamycin, without a distinct effect on IL-6 protein production. In contrast, in mature monocytic blast cells inhibition of the PI3-K signaling route had a stimulatory effect on IL-6 protein secretion. Interestingly, these findings were not specifically linked to the malignant counterpart but were also observed with normal CD34(+) sorted cells vs mature monocytes. Evidence is provided that the Ly294002-induced increase in IL-6 protein secretion is linked to the cAMP dependent signaling pathway and not to changes in the phosphorylation of ERK or p38. However, although the enhanced IL-6 protein secretion is cAMP dependent, it was not found to be mediated by protein kinase A (PKA) or by the GTP-ase Rap1. This study indicates that inhibition of the PI3-K signaling pathway has an inhibitory effect on cell proliferation but a stimulatory effect on IL-6 expression mediated by a cAMP-dependent but PKA-independent route.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063872     DOI: 10.1016/s0301-472x(00)00529-4

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.

Authors:  Siqing Fu; Bryan T Hennessy; Chaan S Ng; Zhenlin Ju; Kevin R Coombes; Judith K Wolf; Anil K Sood; Charles F Levenback; Robert L Coleman; John J Kavanagh; David M Gershenson; Maurie Markman; Kristine Dice; Adrienne Howard; Jane Li; Yang Li; Katherine Stemke-Hale; Mary Dyer; Edward Atkinson; Ed Jackson; Vikas Kundra; Razelle Kurzrock; Robert C Bast; Gordon B Mills
Journal:  Gynecol Oncol       Date:  2012-04-06       Impact factor: 5.482

2.  Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

Authors:  Verena von Felbert; Francisco Córdoba; Jakob Weissenberger; Claudio Vallan; Masashi Kato; Izumi Nakashima; Lasse Roger Braathen; Joachim Weis
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 3.  Genes and pathways driving glioblastomas in humans and murine disease models.

Authors:  Adrian Merlo
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

4.  Phosphoinositide 3 kinase mediates Toll-like receptor 4-induced activation of NF-kappa B in endothelial cells.

Authors:  Xianwu Li; Joan C Tupper; Douglas D Bannerman; Robert K Winn; Christopher J Rhodes; John M Harlan
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 5.  Treatment concepts for elderly patients with acute myeloid leukemia.

Authors:  Wolfgang R Sperr; Alexander W Hauswirth; Friedrich Wimazal; Paul Knöbl; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

6.  Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition.

Authors:  Craig Dorrell; Katsuto Takenaka; Mark D Minden; Robert G Hawley; John E Dick
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

7.  Ribosomal p70S6K basal activity increases upon induction of differentiation of myelomonocytic leukemic cell lines HL60, AML14 and MPD.

Authors:  Julian Gomez-Cambronero; Tricia Frye; Michael Baumann
Journal:  Leuk Res       Date:  2004-07       Impact factor: 3.156

8.  Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness.

Authors:  A L Carey; C R Bruce; M Sacchetti; M J Anderson; D B Olsen; B Saltin; J A Hawley; M A Febbraio
Journal:  Diabetologia       Date:  2004-05-28       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.